转移性去势抵抗性前列腺癌患者中用前列腺特异性膜抗原脉冲处理的树突状细胞：一项系统评价和荟萃分析。
Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis.
作者信息
Mohammadzadeh Mohammad, Shirmohammadi Masoud, Ghojazadeh Morteza, Nikniaz Leila, Raeisi Mortaza, Aghdas Seyed Ali Mousavi
机构信息
Department of Radiology-Radiotherapy-Nuclear Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Gastroenterology, Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
出版信息
Prostate Int. 2018 Dec;6(4):119-125. doi: 10.1016/j.prnil.2018.04.001. Epub 2018 Apr 28.
BACKGROUND
Dendritic cells (DCs) are used in many malignancies as vaccines to induce immunity against specific cancer antigens. The role of DCs in metastatic castration-resistant prostate cancer (mCRPC) is not determined. In this study, the proportion of mCRPC patients with clinically significant response to targeted therapy by DCs pulsed with prostate-specific membrane antigen was evaluated, and the possible adverse effects of this modality were investigated.
METHODS
Major databases were searched up to Feb 2017, to identify studies in which the antitumor efficacy of DCs pulsed with the extracellular portion of PSMA was studied for the treatment of mCRPC. Data were collected by two reviewers and analyzed using Comprehensive Meta-Analysis software, version 2.0.
FINDINGS
Our study consisted of 6 nonrandomized prospective (cohort) trials, overall reporting on 153 mCRPC patients. The event rate that is the representative of fraction of patients showing antitumor response was 0.43 (95% confidence interval = 0.355-0.512; = 0.097). No significant between-study heterogeneity or inconsistency was detected (I = 5.47; Q = 5; = 0.382). Our study failed to demonstrate a significant therapeutic efficacy for DCs in mCRPC. However, no significant adverse effects were seen.
背景
树突状细胞（DCs）在许多恶性肿瘤中被用作疫苗，以诱导针对特定癌症抗原的免疫反应。DCs在转移性去势抵抗性前列腺癌（mCRPC）中的作用尚未确定。在本研究中，评估了经前列腺特异性膜抗原脉冲处理的DCs对靶向治疗有临床显著反应的mCRPC患者的比例，并研究了这种治疗方式可能产生的不良反应。
方法
检索截至2017年2月的主要数据库，以确定研究经PSMA细胞外部分脉冲处理的DCs治疗mCRPC的抗肿瘤疗效的研究。由两名审阅者收集数据，并使用2.0版综合荟萃分析软件进行分析。
结果
我们的研究包括6项非随机前瞻性（队列）试验，总共报告了153例mCRPC患者。代表显示抗肿瘤反应患者比例的事件发生率为0.43（95%置信区间 = 0.355 - 0.512；P = 0.097）。未检测到显著的研究间异质性或不一致性（I² = 5.47；Q = 5；P = 0.382）。我们的研究未能证明DCs对mCRPC有显著的治疗效果。然而，未观察到显著的不良反应。
Zotero 插件